Skip to main content

Table 3 Association between mitotic count (left columns) and CCND1 (right columns) and clinico-pathological variables and other cell proliferation markers

From: Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot

Variable

levels

Mitotic count per 2 mm2

CCND1 copy number ratiob

<  8 / 2 mm2

≥ 8 / 2 mm2

 

<  0

>  0

 

N (%)

N (%)

p valuea

N (%)

N (%)

p valuea

Age

<  65

133 (47)

133 (49)

0.72

101 (49)

129 (48)

0.72

 

≥ 65

150 (53)

141 (51)

 

104 (51)

142 (52)

 

Nodal status

negative

173 (61)

135 (49)

0.005

112 (55)

152 (56)

0.75

 

positive

110 (39)

139 (51)

 

93 (45)

119 (44)

 

T stage

T1–2

262 (93)

235 (86)

0.01

180 (88)

245 (90)

0.36

 

T3–4

21 (7)

39 (14)

 

25 (12)

26 (10)

 

Grade

grade 1–2

279 (99)

90 (33)

< 0.001

142 (69)

171 (63)

0.16

 

grade 3

4 (1)

184 (67)

 

63 (31)

100 (37)

 

PgR

negative

116 (42)

143 (52)

0.02

92 (46)

132 (50)

0.42

 

positive

157 (58)

130 (48)

 

108 (54)

133 (50)

 

Her2

negative

257 (93)

226 (84)

< 0.001

180 (90)

233 (87)

0.46

 

positive

3 (1)

38 (14)

 

13 (7)

22 (8)

 
 

missing

16 (6)

6 (2)

 

7 (4)

12 (4)

 

Ki67

<  5%

104(53)

94 (42)

0.02

72 (54)

92 (46)

0.78

 

≥ 5%

92 (47)

130 (58)

 

88 (55)

106 (54)

 

Cyclin D1

below median

106 (53)

100 (42)

0.02

76 (49)

105 (48)

0.85

 

above median

93 (47)

140 (58)

 

80 (51)

115 (52)

 

mitotic count

<  8 per 2 mm2

283 (100)

0(0)

na

116 (57)

126 (47)

0.03

 

≥ 8 per 2 mm2

0(0)

274 (100)

 

87 (43)

142 (53)

 

CCND1 log 2 copy number ratiob

<  0

116 (48)

87 (38)

0.03

205 (100)

0(0)

na

>  0

126 (52)

142 (62)

 

0(0)

271 (100)

 
  1. aChi-square test, analysis based on cases without missing values
  2. bprobe set 2